


- 35 -

Claims

1. The compounds of general formula (1)



5 in which:

- (a) represents a single bond or a double bond;
- W represents a CH, CH<sub>2</sub>, CHCH<sub>3</sub>, CCH<sub>3</sub> or C(CH<sub>3</sub>)<sub>2</sub> group, a C(CH<sub>2</sub>)<sub>2</sub> group (i.e. a carbon atom bearing two methylene groups linked together so as to form a spiro-cyclopropane unit) or a C(CH<sub>2</sub>)<sub>3</sub> group (i.e. a carbon atom bearing two methylene groups linked to another methylene group so as to form a spiro-cyclobutane unit) with the proviso, however, that when (a) is a double bond, then W exclusively represents a CH or CCH<sub>3</sub> group, and that when (a) is a single bond, then W exclusively represents a CH<sub>2</sub>, CHCH<sub>3</sub>, C(CH<sub>3</sub>)<sub>2</sub>, C(CH<sub>2</sub>)<sub>2</sub> or C(CH<sub>2</sub>)<sub>3</sub> group;
- X is a carbon atom bearing a hydrogen atom (CH) or a nitrogen atom;
- Y is a hydrogen atom or a fluorine atom;


their addition salts and optionally the hydrates of the addition salts with pharmaceutically acceptable inorganic acids or organic acids and their tautomeric forms, the pure enantiomers and mixtures of racemic or nonracemic enantiomers.

2. The derivatives as claimed in claim 1, characterized in that they are chosen from the following compounds:

- [2-(2,2-dimethyl-2,3-dihydrobenzofuran-7-yloxy)ethyl]-(3-cyclopenten-1-ylbenzyl)amine;
- [2-(benzofuran-7-yloxy)ethyl]-(3-cyclopenten-1-ylbenzyl)amine;
- [2-(2-methylbenzofuran-7-yloxy)ethyl]-(3-cyclopenten-

- 1-ylbenzyl) amine;  
[2-(2,3-dihydrobenzofuran-7-yloxy)ethyl]-(3-cyclopenten-1-ylbenzyl) amine;  
[2-(2-spirocyclopropyl-2,3-dihydrobenzofuran-7-yloxy)-ethyl]-(3-cyclopenten-1-ylbenzyl) amine;  
[2-(2,2-dimethyl-2,3-dihydrobenzofuran-7-yloxy)ethyl]-[3-(2-fluorocyclopenten-1-yl)benzyl] amine;  
[2-(2,2-dimethyl-2,3-dihydrobenzofuran-7-yloxy)ethyl]-(5-cyclopenten-1-ylpyridine-3-ylmethyl) amine;  
their addition salts and optionally the hydrates of addition salts with pharmaceutically acceptable inorganic acids or organic acids and their isomers and their tautomers.

3. A compound of formula (2):



- in which **X** and **Y** have the same meaning as in formula (1) as synthesis intermediate involved in the preparation of the compounds of formula (1).

4. A compound as claimed as claimed in either of claims 1 and 2, as medicaments.

5. A pharmaceutical composition, characterized in that it contains, as active ingredient, at least one compound as claimed in either of claims 1 and 2 combined with an inert pharmaceutical carrier or other pharmaceutically acceptable vehicles and optionally with another medicament.

6. The pharmaceutical composition as claimed in claim 5, which is useful in the treatment of schizophrenia or useful in the treatment of the progression of schizophrenia.